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Adding prebiotics or probiotics to infant formula to improve the intestinal flora of formula-fed infants is considered to be a major innovation. Several com-
panies have brought relevant formulations onto the market. However, comparative data on the effects of pre- and probiotics on the intestinal microflora of
infants are not available. The present study aimed to compare the effects of infant formula containing a mixture of galacto- and fructo-oligosaccharides or
viable Bifidobacterium animalis on the composition and metabolic activity of the intestinal microflora. Before birth, infants were randomised and double
blindly allocated to one of three formulas. The prebiotic (GOS/FOS) group (n 19) received regular infant formula supplemented with a mixture of galacto-
oligosaccharides and fructo-oligosaccharides (6 g/l). The probiotic (Bb-12) group (n 19) received the same formula supplemented with 6·0 £ 1010 viable
cells of B. animalis per litre. The standard group (n 19) received non-supplemented regular formula. A group of sixty-three breast-fed infants was included
as a reference group. Faecal samples were taken at postnatal day 5 and 10, and week 4, 8, 12 and 16. Compared with the groups fed Bb-12 and standard
formula, the GOS/FOS formula group showed higher faecal acetate ratio (69·7% (SEM 2·7), 69·9% (SEM 3·9) and 82·2% (SEM 5·3); P,0·05) and lactate
concentration (11·3 (SEM 7·9), 3·1 (SEM 2·3) and 34·7 (SEM 10·7) mmol/kg faeces) and lower pH (6·6 (SEM 0·2), 7·1 (SEM 0·2) and 5·6 (SEM 0·2); P,0·05) at
16 weeks. Differences in percentage of bifidobacteria between the GOS/FOS (59·2% (SEM 7·7)), Bb-12 (52·7% (SEM 8·0)) and the standard (51·8% (SEM
6·4)) groups were not statistically significant at 16 weeks. Feeding infants GOS/FOS formula resulted in a similar effect on metabolic activity of the flora as
in breast-fed infants. In the Bb-12 group, composition and metabolic activity of the flora were more similar to those of the standard group.
Infants: Prebiotics: Probiotics: Galacto-oligosaccharides: Fructo-oligosaccharides: Bifidobacteria: Short-chain fatty acids: Lactate: pH
In breast-fed infants the intestinal microflora is dominated by bifi-
dobacteria. In general, formula-fed infants have a more diverse
flora (Bullen & Tearle, 1976; Benno et al. 1984; Balmer et al.
1989; Chierici et al. 1997; Harmsen et al. 2000). Fermentation
by intestinal microflora results in the production of SCFA,
which have different functions such as an energy source for colo-
nocytes, regulating cell growth, lowering intestinal pH and inhi-
biting the growth of pathogens (Wang & Gibson, 1993).
Branched SCFA, products of protein breakdown by intestinal bac-
teria, are potentially harmful. In breast-fed infants, the microflora
produces high amounts of acetate and lactate which in combi-
nation with a lower pH restricts the growth of potential pathogens
like Escherichia coli and Clostridium perfringens (Eklund, 1983;
Wang & Gibson, 1993). In formula-fed infants, relatively high
amounts of propionate and butyrate are found.
Complex neutral oligosaccharides have been identified as the
most likely prebiotic factor in human milk that stimulates the
growth of bifidobacteria in the infant gut (Brand et al. 1998;
Engfer et al. 2000). Prebiotics are defined as ‘non-digestible
food ingredients that beneficially affect the host by selectively sti-
mulating the growth and/or activity of one or a limited number of
bacteria in the colon, and thus improve host health’ (Gibson &
Roberfroid, 1995). Like human milk oligosaccharides, prebiotics
in infant nutrition stimulate the growth of bacteria that are already
present in the large intestine. Several investigators have reported
on approaching the prebiotic effect of human milk oligosacchar-
ides by using a mixture of 90% galacto-oligosaccharides (GOS)
and 10% fructo-oligosaccharides (FOS) in regular infant formula
(Boehm et al. 2002; Moro et al. 2002). It was found that feeding
infants GOS/FOS formula significantly increased the number of
bifidobacteria.
Besides prebiotics, another approach to improve the intestinal
microflora is to add probiotics to infant formula (Langhendries
et al. 1995). Probiotics were originally defined as ‘live microbial
food supplements which beneficially affect the host animal by
improving its intestinal microbial balance’ (Fuller, 1989). The
possible role of specific probiotic bacteria in recovery from
atopic disease and treatment of rotavirus diarrhoea in children
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was elucidated in several studies (Isolauri et al. 2000; Kalliomaki
et al. 2001). However, to date, only one study has focused on the
effects of probiotics on the intestinal microflora of infants (Lan-
ghendries et al. 1995).
Recognising the possible health benefits of a gut flora dominated
by bifidobacteria, the question is whether pre- or probiotics should
be used to reach the best possible effect. In the present study, we
investigated the effects of adding either prebiotic oligosaccharides
or probiotic bacteria, to the same standard infant formula, on the
composition and metabolic activity of the intestinal microflora in
infants. Tomake an optimal comparison of the prebiotic and probio-
tic formulas, the study was performed in one population under com-
parable environmental conditions. We hypothesised that infants fed
either prebiotics or probiotics will develop an intestinal microflora
dominated by bifidobacteria. Bifidobacteria produce acetate and
lactate, which have a lowering effect on intestinal pH. Therefore,
similar to breast-fed infants, we expected to find a lower pH,
higher ratios of acetate and higher amounts of lactate in the faeces
of infants fed prebiotic and probiotic formulas, compared with
infants fed standard formula.
Subjects and methods
Subjects
Sixty-three pregnant women who had decided to breast-feed, and
fifty-seven who had chosen not to, were recruited during their last
trimester of pregnancy. Infants with normal birth weight and no
congenital abnormality, congenital disease or gastrointestinal dis-
ease were enrolled within 3 d after delivery. The study was
approved by the ethical committee of the Medical Centre St. Rad-
boud, Nijmegen, The Netherlands. Written informed consent was
obtained from the parents before enrolment in the study.
Feeding groups
Infants of mothers who had decided not to breast-feed were ran-
domly and double blindly allocated to one of three formula
groups (GOS/FOS, Bb-12 or standard). Randomisation included a
block size of 3 and was carried out by a person not involved in the
study. The formula tins containing the different products were
coded using a number the infants received at inclusion. The standard
formula group (n 19) received a regular, non-supplemented infant
formula (Nutrilon I; Nutricia, Zoetermeer, The Netherlands). The
main compositional data of the standard formula at the standard
dilution of 131 g/l are given in Table 1. The prebiotic formula
group (GOS/FOS; n 19) received the same standard infant formula
supplemented (6 g/l) with a mixture of trans-galacto-oligosacchar-
ides (VivinalGOS;BorculoDomo Ingredients, Zwolle, TheNether-
lands) and fructo-oligosaccharides (RaftilineHPFOS;Orafti Active
Food Ingredients, Tienen, Belgium). The mixture comprised 90%
GOS and 10% FOS in order to closely resemble the spectrum of
molecular masses of the neutral oligosaccharide fraction in human
milk (Stahl et al. 1994). The probiotic formula group (Bb-12; n
19) received the standard infant formula supplemented with
6·0 £ 1010 viable cells of Bifidobacterium animalis per litre (Chris-
tian Hansen Ltd, Hørsholm, Denmark). B. animalis strain Bb-12
(sometimes referred to as B. lactis) is a thoroughly investigated pro-
biotic andhas been found to survive passage through the gastrointes-
tinal tract of adults and infants (Langhendries et al. 1995;
Fukushima et al. 1998; Alander et al. 2001). Several studies have
demonstrated that during a period of daily ingestion of viable Bb-12
cells, the number of faecal bifidobacteria increases significantly
(Link-Amster et al. 1994; Schiffrin et al. 1995; Alander et al. 2001).
The shelf life of the probiotic formula was tested during storage.
After 12 months of storage, 1·0 £ 1010 (SEM 0·5 £ 1010) colony-
forming units of B. animalis were recovered. The study formulas
were fed ad libitum during the study period.Motherswere instructed
to heat the water to a maximal temperature of 45 8C before adding
the milk powder. This was to avoid hot spots in the liquid milk
during microwaving, possibly leading to killing of the bacteria.
Motherswho had decided to breast-feedwere stimulated to continue
breast-feeding during the course of the study and were supported by
a lactation consultant when needed. At termination of breast-feed-
ing their infants received one of the three formulas. Compliance
was assessed by counting the number of unused formula tins
during each visit and comparing the amount of formula consumed
with the recorded food intake.
Questionnaires
Demographic, clinical and anthropometric data of the mother
were collected prior to delivery. Information on delivery was
obtained from the mother at day 5 after delivery. Information
on the infants’ food intake, formula tolerance, stool character-
istics, health and anthropometrics was obtained from question-
naires at postnatal day 5, 10 and 28 and once every 4 weeks
thereafter until the end of the study.
Faecal samples
Parents were asked to take faeces samples from their infants, at
postnatal day 5, 10, 28 and once every 4 weeks thereafter. The
samples were taken from the diaper as soon as possible after defe-
cation, collected in faeces containers (Greiner Labortechnik,
Alphen a/d Rijn, The Netherlands) and stored immediately at
220 8C by the parents. During the study period, the investigators
visited the participants regularly, to collect faeces samples and
Table 1. Composition of the study formulas per litre
Standard
formula
GOS/FOS
formula
Bb-12
formula
Energy (kJ) 2800 2800 2800
Protein (g) 14 14 14
Casein:whey 40:60 40:60 40:60
Fat (g) 35 35 35
Total carbohydrates (g) 75 75 75
GOS (g) – 5·4 –
FOS (g) – 0·6 –
Lactose (g) 75 67 75
Glucose (g) – 2 –
Bb-12 (CFU) – – 6·0 £ 1010
Minerals
Ca (mg) 540 540 540
P (mg) 270 270 270
Mg (mg) 50 50 50
Na (mg) 190 190 190
K (mg) 680 680 680
Cl– (mg) 430 430 430
Fe (mg) 5 5 5
Zn (mg) 5 5 5
GOS, galacto-oligosaccharides; FOS, fructo-oligosaccharides; Bb-12, Bifidobacterium
animalis strain Bb-12; CFU, colony-forming units.
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questionnaires. Infant formula was supplied on request. Faeces
samples were transported to the laboratory in a portable freezer
(minimal temperature 215 8C, MRFD-015; Veba Meditemp,
Uden, The Netherlands).
Preparation of faecal samples
For the determination of SCFA, 1 g of faeces was thawed in iced
water, diluted 10 £ in MilliQ and homogenised for 10min using
a stomacher (IUL Instruments, Barcelona, Spain). Then 350ml of
homogenised faeces was mixed with 200ml formic acid (5%, by
vol.), 100ml 2-ethylbutyric acid (1·25 g/l; Sigma-Aldrich, Zwijn-
drecht, The Netherlands) and 350ml MilliQ. The samples were
centrifuged for 5min at 15 000 g to remove large particles and
the supernatant was stored at 220 8C.
For the fluorescence in situ hybridisation (FISH) analysis and
lactic acid measurements, the samples were thawed in iced water,
diluted 10 £ (w/v) in PBS, pH 7·4, and homogenised for 10min
using a stomacher. The homogenised faeces were stored at220 8C.
Fluorescence in situ hybridisation
FISH analysis was performed as described previously (Langen-
dijk et al. 1995; Jansen et al. 1999; Harmsen et al. 2000) with
some slight modifications. Paraformaldehyde-fixed samples were
applied to gelatine-coated glass slides (polytetrafluoroethylene-
coated eight-well (1 cm2/well) object slides; CBN lab suppliers,
Drachten, The Netherlands) and air-dried. The dried samples
were dehydrated in 96% ethanol for 10min. Hybridisation
buffer (20mM-Tris–HCl, 0· 9 M-NaCl, 0·1% SDS; pH 7·2) with
Cy3-labelled Bifidobacterium-specific probe Bif164mod (50-
CAT CCG GYA TTA CCA CCC; 10 ng/ml), was preheated and
added to the dried samples. Bif164mod is modified version of
probe S-G-Bif-0164-a-A-18 (Langendijk et al. 1995), which
detects the presence of bifidobacteria including the B. animalis
species (Satokari et al. 2001). The slides were incubated over-
night in a dark moist chamber at 50 8C. After hybridisation the
slides were washed for 30min in 50ml of preheated washing
buffer (20mM-Tris–HCl, 0·9 M-NaCl; pH 7·2) and briefly
rinsed in MilliQ. For staining all bacteria, the samples were incu-
bated with 0·25 ng 40,6-diamidino-2-phenylindole (DAPI)/ml in
PBS for 5min at room temperature. After DAPI staining the
slides were briefly rinsed in MilliQ, dried, mounted with Vecta-
shield (Vector Laboratories, Burlingame, CA, USA) and covered
with a coverslip. The slides were automatically analysed using an
Olympus AX70 epifluorescence microscope with automated
image analysis software (Analysis 3.2; Soft Imaging Systems
GmbH, Mu¨nster, Germany). The percentage of bifidobacteria
per sample was determined by analysing twenty-five randomly
chosen microscopic positions. At each position the percentage
of bifidobacteria was determined by counting all cells with a
DAPI filter set (SP100; Chroma Technology Corp., Brattleboro,
VT, USA) and counting all bifidobacteria using a Cy3 filter set
(41 007; Chroma Technology Corp.).
Short-chain fatty acid analysis
The SCFA acetic, propionic, n-butyric, isobutyric and n-valeric
acids were quantitatively determined using a Varian 3800 gas
chromatograph (Varian, Inc., Walnut Creek, CA, USA) equipped
with a flame ionisation detector. The sample (0·5ml) was injected
at 80 8C into the column (Stabilwax, 15m £ 0·53mm, film thick-
ness 1·00mm; Restek Co., Bellafonte, PA, USA) using He as car-
rier gas (20·7 kPa). New columns were conditioned overnight at
200 8C. After injection of the sample, the oven was heated to
160 8C at a rate of 16 8C/min, followed by heating to 220 8C at
20 8C/min and finally maintained at a temperature of 220 8C for
1·5min. The temperature of the injector and the detector was
200 8C. After every ten samples the column was cleared by injec-
tion of 0·5ml formic acid (1%, by vol.) to avoid memory effects
of the column, followed by injection of 0·5ml standard SCFA mix
(1·77mM-acetic acid, 1·15mM-propionic acid, 0·72mM-n-butyric
acid, 0·72mM-isobutyric acid, 0·62mM-n-valeric acid; Sigma-
Aldrich) to monitor the occurrence of memory effects. SCFA con-
centrations were determined using 2-ethylbutyric acid as an
internal standard. Faecal SCFA concentrations are dependent on
the consistency of stools.
Lactate
Homogenised faeces were thawed on ice and centrifuged for 5min
at 14 000 rpm, then 100ml of the supernatant was heated for 10min
at 100 8C to inactivate all enzymes. Lactate was determined enzy-
matically using an L-lactic acid detection kit with D- and L-lactate
dehydrogenase (Boehringer Mannheim, Mannheim, Germany).
pH
After storage at220 8C, faecal sampleswere thawed and the pHwas
measured directly in the faeces at room temperature using a Handy-
lab pHmeter (Schott Glas,Mainz, Germany) equippedwith an Inlab
423 pH electrode (Mettler Toledo, Columbus, OH, USA).
Data analysis
Prior to the study, power calculations showed that to detect a
difference in the percentage of bifidobacteria between the inter-
vention formula groups (GOS/FOS and Bb-12) and the standard
formula group of 30% with SD of 25%, thirteen infants should
be included per group. Because of an expected drop-out of
30% in the formula groups, more infants than calculated were
included in the study. The SPSS statistical package (version
11.0; SPSS Inc., Chicago, IL, USA) was used for analysis of
the results. All values were checked for normality by visual
inspection of the normal probability plots. Differences in percen-
tage of bifidobacteria, pH, relative amounts of SCFA and lactate
between the groups were tested for significance using ANOVA. In
the case of a significant difference (P,0·05), groups were com-
pared by using the Bonferroni post hoc test.
Because it is not possible to assign breast- and bottle-feeding
double blindly and to ensure adequate randomisation, no statisti-
cal analyses were performed to compare the breast-feeding group
with any of the formula feeding groups. When an infant changed
from breast- to formula feeding, it was considered a drop-out and
only the samples taken during the period of complete breast-feed-
ing were included in the study. Samples taken after the switch
from breast- to formula feeding were not included in the study.
Results
In total, 120 infants were included in the study between
January 2000 and May 2003. Fifty-seven infants started on
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formula feeding directly after birth and were divided equally
among the formula groups. Of the sixty-three infants who were
fed breast milk directly after birth, twenty-four switched to for-
mula feeding before the age of 16 weeks and five infants dropped
out. The characteristics of the study subjects are shown in Table
2. In the formula groups, thirteen infants dropped out of the study
within the first 16 weeks after birth: four in the standard group,
five in the GOS/FOS group and four in the Bb-12 group. Reasons
for dropping out included colic, suspicion of cows’ milk allergy,
constipation and practical problems.
Faecal bifidobacteria
The percentage of bifidobacteria in the faeces of infants at the age of
5 d, 10 d, and 4, 8, 12 and 16weeks is shown in Fig. 1 for the different
feeding groups. Although not statistically significant, the GOS/FOS
group tends to have a higher percentage of bifidobacteria in the total
bacterial count at all ages compared with the standard and Bb-12
formula groups. Percentages of bifidobacteria in the formula
groups are comparable to that found in the breast-fed group.
pH
The pH values measured in the faeces of the formula-fed infants are
shown in Fig. 2. The lowest pH was found in infants fed on breast
milk. Faecal pH of infants fed the GOS/FOS formula was lower
than in the standard (P,0·05 at all ages except 5 d) and the Bb-12
formula groups (P,0·05 from week 8 on). At age 10 d, the faecal
pH of infants fed the Bb-12 formula was significantly lower than
that in the standard formula group (P¼0·001).
Short-chain fatty acids
The total amount of SCFA in the faeces is shown in Table 3. The
percentages of the different SCFA from the total amount of SCFA
are shown in Table 4. The table includes data from all available
faeces samples that were large enough (0·5ml) to perform the
SCFA analysis. There were no statistically significant differences
in total SCFA concentration found between the formula groups.
However, already after 10 d, differences in SCFA profiles could
be seen between infants fed on GOS/FOS formula and infants
fed on standard or Bb-12 formula. Infants fed the GOS/FOS for-
mula had higher percentages of acetate and lower percentages of
propionate, butyrate and iC4-5 SCFA (isobutyrate, isovalerate and
valerate) compared with infants fed the standard or the Bb-12 for-
mula. There were no differences in the relative amounts of SCFA
in the faeces of infants fed Bb-12 formula compared with infants
fed the standard formula.
Lactate
The concentrations of lactate (mmol/kg faeces) in all groups are
shown in Table 3. Already from 5 d of age, the GOS/FOS formula
group (NS) and the group fed on breast milk had higher amounts
of faecal lactate than did the standard and Bb-12 formula groups.
No differences were found between the Bb-12 group and the stan-
dard formula group.
Discussion
With the aim of stimulating the typical intestinal microbial ecology
of breast-fed infants in formula-fed infants, the present study com-
pared the effects of adding either prebiotics or probiotics to a stan-
dard infant formula. We found that infant formula containing a
mixture of GOS and long-chain FOS induced a metabolic activity
of the intestinal microflora similar to that in breast-fed infants
(high acetate, lactate and low pH). We also observed that infant for-
mula containing viable bifidobacteria induced a metabolic activity
comparable to that in infants fed standard infant formula (SCFApat-
tern typical for mixed-type flora, neutral pH).
To investigate whether infant formula containing pre- or pro-
biotics can induce an intestinal microflora comparable to that in
breast-fed infants, one should ideally compare the results of
both formula groups with those observed in the breast-fed
group. However, we did not statistically compare the breast-feed-
ing group with the formula feeding groups because it is not
possible to randomise and double blindly assign infants to
breast-feeding and also because of the obvious selection bias
due to social and educational differences between breast- and for-
mula feeding mothers (Ford & Labbok, 1990). By limiting stat-
istical analysis to the formula groups, we are still able to
compare the effect of the prebiotic and probiotic component on
gut flora.
Although all formulas were well accepted and tolerated, thir-
teen of the fifty-seven formula-fed infants dropped out before
the age of 16 weeks. The number of drop-outs was not signifi-
cantly different (P¼0·334) between groups. The reasons given
for dropping out were similar between the feeding groups,
which therefore did not give rise to selection bias.
Despite different product compositions and the somewhat
lower dosage of GOS/FOS in the present study (0·6 g/100ml),
the percentage of bifidobacteria found in the GOS/FOS group
(64% at 8 weeks of age) is similar to that observed by other
investigators: 76% after 6 weeks, 0·8 g/100ml (Schmelzle et al.
2003), 69% after 6 weeks, 0·8 g/100ml (Knol et al. 2003); and
65% after 6 weeks, 0·8 g/100ml (Knol et al. 2002). For unknown
reasons, the percentage of bifidobacteria in the standard formula
group in the present study is higher than that observed previously.
Differences in composition of the formula (other than the carbo-
hydrates) may play a role.
Results of the probiotic group are difficult to compare with
other studies because, to date, only one study has reported the
Table 2. Characteristics of the study subjects
Standard
formula
(n 19)
GOS/FOS
formula
(n 19)
Bb-12
formula
(n 19)
Breast
milk
(n 63)
Sex
Male 5 12 10 33
Female 14 7 9 30
Place of birth
At home 7 8 10 40
Hospital 12 11 9 23
Mode of delivery
Vaginal 14 16 18 59
Caesarean section 5 3 1 4
Birth weight (g)
Mean 3601 3318 3481 3651
SD 501 602 524 601
GOS, galacto-oligosaccharides; FOS, fructo-oligosaccharides; Bb-12, Bifidobacterium
animalis strain Bb-12.
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effect of a probiotic infant formula on the intestinal microflora but
did not give any quantitative data on the stimulation of bifidobac-
teria (Langhendries et al. 1995).
In the present study, we found that feeding infants an infant for-
mula supplemented with a mixture of GOS and long-chain FOS
has a marked effect on the metabolic activity of the intestinal
microflora. In general, the pH and relative amounts of SCFA in
faeces of our breast-fed group and the standard formula group
are similar to the findings of others (Ogawa et al. 1992; Siigur
et al. 1993; Edwards et al. 1994). However, the relative amounts
of SCFA, the lactate concentration and the pH in the faeces of the
GOS/FOS group are comparable to values seen in breast-fed
infants. High relative amounts of acetate and high concentrations
of lactate, together with the low faecal pH, create conditions that
are less favourable (colonisation resistance) for Enterobacteria-
ceae and other potential opportunistic pathogens that can be
Fig. 1. Percentage of bifidobacteria from total number of bacterial cells per gram of faeces (wet weight) in infants fed breast milk ( -A- -), formula supplemented
with a mixture of galacto-oligosaccharides and fructo-oligosaccharides (6 g/l; —O—), formula supplemented with Bifidobacterium animalis strain Bb-12 (6·0 £ 1010
viable cells/l; —V—) and standard formula (—f—), between birth and 16 weeks of age (d, day; w, week). Values are means with their standard error shown by
vertical bars. No statistically significant differences were found between groups (P.0·05).
Fig. 2. pH values of faeces in infants fed breast milk (- -A- -), formula supplemented with a mixture of galacto-oligosaccharides and fructo-oligosaccharides (6 g/l;
—O—), formula supplemented with Bifidobacterium animalis strain Bb-12 (6·0 £ 1010 viable cells/l; —V—) and standard formula (—f—), between birth and 16
weeks of age (d, day; w, week). Values are means with their standard error shown by vertical bars. Mean values were significantly different from those of the stan-
dard formula group: *P,0·05. Mean values were significantly different from those of the Bb-12 formula group: †P,0·05.
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present in low numbers or obtained from the environment (Moon,
1983; Adams & Hall, 1988). As in breast-fed infants, the relative
amounts of faecal butyrate and propionate in the GOS/FOS group
are lower than in the standard and Bb-12 groups. This indicates
that in the groups fed breast milk and GOS/FOS the intestinal
microflora contains lower numbers of butyrate- and propionate-
producing bacteria such as Clostridium and Bacteroides. Butyrate
is an important fuel for the colonic mucosa in adults, where it
stimulates intestinal mucosal cell proliferation, but because of
low faecal levels in breast-fed infants, it is considered less import-
ant for infants. The low faecal concentration of iC4-5 SCFA (iso-
butyrate, isovalerate and valerate) and low faecal pH that were
seen in the GOS/FOS and breast-fed groups indicate that protein
fermentation by e.g. E. coli is low.
The major difference with other studies using the GOS/FOS
mixture is the relatively high percentage of bifidobacteria in the
standard formula group, which prevented us from finding statisti-
cally significant differences in bacterial composition. This finding
was rather unexpected and warrants further discussion. The clear
difference between the standard formula group and the prebiotics
group with respect to all parameters of intestinal microbial meta-
bolic activity including pH, and the similarity with the findings in
the breast-fed group, indicates a distinct effect of the GOS/FOS
mixture. A possible explanation for the discrepancy between the
findings in metabolic activity and those of microbial analysis
might be found in the presumption that the GOS/FOS mixture
used in the present study predominantly stimulated the growth
of other lactic acid-producing bacteria like Lactobacillus
(Bullen & Tearle, 1976; Edwards et al. 1994). In fact, the prebio-
tic mixture, which contains low- as well as high-molecular-mass
oligosaccharides, was designed to create optimal growth con-
ditions for both bifidobacteria and lactobacilli (Boehm et al.
2002). No specific FISH probe is available for lactobacilli, and
new methods need to be developed for their accurate quantifi-
cation. Another possibility is that although high numbers of bifi-
dobacteria were present in the standard and Bb-12 formula
groups, the metabolic activity of the bacteria was low due to lim-
iting substrate availability. Small amounts of lactose that escaped
digestion in the small intestine might have stimulated bifidobac-
terial growth in the standard and Bb-12 formula groups without
providing sufficient amounts of substrate for full-blown metabolic
activity (MacLean et al. 1983). This could have led to less acetate
and lactate production and subsequently higher pH. Different
from traditional plating methods, the FISH method used in the
present study does not make a distinction between metabolically
active and inactive bacteria (Harmsen et al. 2000).
In the Bb-12 group the percentage of bifidobacteria was already
very high after 5 d (65%), but declined during the first 16 weeks
of life to 53% and no significant differences with the other groups
were found. This initial rapid colonisation might be expected
because space and nutrients are not limiting. However, based on
the metabolic activity parameters showing a closer proximity of
the Bb-12 group to the standard formula group, we conclude
that a strong bifidogenic effect of the Bb-12 formula is unlikely.
In the present study, adding viable B. animalis strain Bb-12 to a
standard infant formula did not have a distinct effect on the
number of bifidobacteria and metabolic activity of the intestinal
microflora. Nevertheless, several studies have shown that specific
probiotic bacteria including strain Bb-12 may have a role in the
prevention and treatment of different diseases (Saavedra et al.
1994; Isolauri et al. 2000; Isolauri, 2001). According to theT
a
b
le
3
.
C
o
n
c
e
n
tr
a
ti
o
n
o
f
la
c
ta
te
(m
m
o
l/
k
g
fa
e
c
e
s
)
a
n
d
to
ta
l
s
h
o
rt
-c
h
a
in
fa
tt
y
a
c
id
s
(m
m
o
l/
k
g
fa
e
c
e
s
)
in
th
e
fa
e
c
e
s
o
f
in
fa
n
ts
,
b
e
tw
e
e
n
b
ir
th
a
n
d
1
6
w
e
e
k
s
o
f
a
g
e
,
o
f
th
e
d
if
fe
re
n
t
s
tu
d
y
g
ro
u
p
s
*
(M
e
a
n
v
a
lu
e
s
w
it
h
th
e
ir
s
ta
n
d
a
rd
e
rr
o
r
a
n
d
n
u
m
b
e
r
o
f
d
e
te
rm
in
a
ti
o
n
s
)
5
d
a
y
s
1
0
d
a
y
s
4
w
e
e
k
s
8
w
e
e
k
s
1
2
w
e
e
k
s
1
6
w
e
e
k
s
M
e
a
n
S
E
n
M
e
a
n
S
E
n
M
e
a
n
S
E
n
M
e
a
n
S
E
n
M
e
a
n
S
E
n
M
e
a
n
S
E
n
S
ta
n
d
a
rd
fo
rm
u
la
L
a
c
ta
te
1
4
·0
7
·7
1
3
4
·7
3
·0
1
9
5
·5
3
·0
1
6
7
·5
6
·4
1
5
1
3
·3
8
·9
1
5
2
·7
1
·3
1
4
S
C
F
A
5
4
·7
1
2
·6
1
2
6
2
·0
7
·9
1
5
6
8
·3
1
0
·3
1
3
7
6
·5
1
3
·2
1
4
7
3
·9
1
1
·9
1
4
6
8
·6
1
4
·0
1
2
G
O
S
/F
O
S
fo
rm
u
la
L
a
c
ta
te
1
0
·7
4
·3
1
4
1
2
·5
3
·7
1
8
1
4
·6
4
·4
1
7
2
7
·8
5
·3
1
8
2
7
·3
7
·7
1
3
4
0
·9
1
0
·7
1
4
S
C
F
A
5
6
·5
7
·7
1
1
6
2
·3
7
·4
1
6
8
3
·1
8
·8
1
5
7
6
·0
8
·4
1
6
7
6
·1
1
2
·2
1
3
6
7
·7
1
1
·7
1
4
B
b
-1
2
fo
rm
u
la
L
a
c
ta
te
1
4
·0
4
·8
1
9
8
·2
3
·9
1
7
5
·3
1
·8
1
7
1
4
·9
6
·6
1
7
3
·6
2
·1
1
6
6
·1
4
·2
1
5
S
C
F
A
6
0
·7
6
·2
1
6
5
8
·3
9
·2
1
2
8
8
·3
1
1
·5
1
4
9
1
·9
1
5
·8
1
6
7
6
·7
1
1
·9
1
3
9
8
·2
1
6
·7
1
5
B
re
a
s
t
m
ilk
L
a
c
ta
te
1
3
·6
2
·8
4
3
1
5
·5
3
·3
4
4
2
2
·9
4
·4
3
5
3
1
·6
5
·3
3
1
4
2
·5
7
·2
2
6
4
5
·2
9
·0
2
2
S
C
F
A
4
8
·7
4
·4
3
2
5
4
·7
4
·9
3
3
5
9
·8
4
·8
2
8
6
2
·8
5
·4
2
2
6
0
·4
4
·9
2
4
5
9
·2
6
·9
1
7
G
O
S
,
g
a
la
c
to
-o
lig
o
s
a
c
c
h
a
ri
d
e
s
;
F
O
S
,
fr
u
c
to
-o
lig
o
s
a
cc
h
a
ri
d
e
s
;
B
b
-1
2
,
B
ifi
d
o
b
a
c
te
ri
u
m
a
n
im
a
lis
s
tr
a
in
B
b
-1
2
.
*N
o
s
ta
ti
s
ti
c
a
lly
s
ig
n
ifi
c
a
n
t
d
if
fe
re
n
c
e
s
w
e
re
fo
u
n
d
b
e
tw
e
e
n
g
ro
u
p
s
(P
.
0
·0
5
).
A. M. Bakker-Zierikzee et al.788
original definition by Fuller (1989), probiotics should change
microbial balance to have a health effect. Our results do not sup-
port such an effect on microflora of a widely used probiotic strain
(B. animalis, Bb-12). It is possible that health effects of the pro-
biotic strain Bb-12 already occur in the small intestine or do not
require major changes in the intestinal microflora more distally.
In conclusion, feeding infants a formula containing the prebio-
tic GOS/FOS mixture resulted in high relative amounts of faecal
acetate, high concentration of faecal lactate and a low faecal pH.
In the infants who received the standard formula or the formula
with added viable cells of B. animalis strain Bb-12, a similar
microflora and metabolic activity were found. Comparison of
the results of the formula groups with the breast-fed group reveals
a similar effect on metabolic activity of the intestinal flora in the
prebiotic formula group only. The observed shift from a more
proteolytic (putrefaction) to a more saccharolytic colon physi-
ology could be considered a health benefit for the infant.
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